Palobiofarma has started the recruitment of a Phase I clinical trial evaluating the safety and tolerability of the novel PDE10/A2a dual antagonist PBF-999 in patients with solid tumors. The trial will be conducted at the Vall D Hebron Hospital, in Barcelona, Spain.